# NCT02420717 (NCT02420717)

> Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02420717
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Recurrent B Acute Lymphoblastic Leukemia; Recurrent Ph-Like Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia; Refractory Ph-Like Acute Lymphoblastic Leukemia
- Interventions: Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Laboratory Biomarker Analysis; Leucovorin; Mercaptopurine; Methotrexate; Prednisone; Rituximab; Ruxolitinib Phosphate; Vincristine
- Enrollment: 11
- Primary outcome: Maximal Tolerated Dose (MTD) of Ruxolitinib in Combination With Chemotherapy Defined as the Highest Dose Level at Which no More Than 1 Out of 6 Patients Experience a Dose Limiting Toxicity (Phase I)
- Primary outcome: Participants With Complete Response (Complete Response [CR]/CR With Incomplete Marrow Recovery [CRi]) (Phase II)

## Indexed commentary on NCT02420717 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02420717